Facing New Challenges in the Delivery of Cancer Care

Web Exclusives - AVBCC COVID-19 Webcast Series

In the Association for Value-Based Cancer Care (AVBCC) webcast, Managed Care Payers: COVID-19 Impact on Cancer Care and Road to Recovery, Michael Kolodziej, MD, Senior Advisor, ADVI Health, moderated a question-and-answer–style discussion featuring 3 experts from the field who shared fresh insights on the unfolding pandemic crisis.

“The vast majority of working-age Americans have their health insurance through employer-sponsored health benefits, so what’s happening in the commercial space is really, really important. It’s important now, and it’s going to be very important as we start to open up America,” said Dr Kolodziej as an introduction to the conversation.

John Fox, MD, Associate Vice President of Medical Affairs, Priority Health, focused first on the impact that telemedicine will have on the way in which claims would be processed and paid going forward. He said that one of the most pressing things is going to be “how to reduce the total cost of care,” noting that the “incorporation of personalized medicine in the cancer space is a great opportunity for doing that.” The other panelists agreed that telemedicine would be a game changer, but which changes would be enduring was an open question.

Panelists also discussed the extent to which their various markets are seeing large numbers of patients who have contracted the virus. Steven Peskin, MD, MBA, FACP, Executive Medical Director, Population Health and Transformation, Horizon BCBS, said, “in New Jersey, Bergen County alone has over 15,000 cases and over 1000 deaths.” Numbers are lower in some of the other, sparsely populated counties; however, “northern New Jersey is part of the Greater New York City area,” and thus reflects what is happening there. In that part of the state, “Our lives have been majorly affected; people are strained by social distancing, and people have lost jobs,” said Dr Peskin.

Bryan Loy, MD, MBA, Physician Lead, Oncology, Laboratory, and Personalized Medicine, Humana, said, “We’ve got to ‘learn our way into this’ with safety first.” As the crisis continues to develop, “paying close attention to where there are resistance factors, whether they be economic or administrative burdens,” will be crucial, Dr Loy concluded.

Related Items
Potential for Anti-Cancer Agents in the Treatment of COVID-19
Web Exclusives published on July 20, 2020 in AVBCC COVID-19 Webcast Series
Oncology Home Infusions in the Post–COVID-19 World
Web Exclusives published on July 20, 2020 in AVBCC COVID-19 Webcast Series
AVBCC Webcast Highlights: COVID-19 Impact on Cancer Care and Road to Recovery
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AVBCC COVID-19 Webcast Series
Economic Impact of the COVID-19 Crisis
Web Exclusives published on June 2, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
Actuarial View of COVID-19: Payers, Providers, and Healthcare Reform
Web Exclusives published on June 2, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
Washington and COVID-19: The Government Response
Web Exclusives published on May 26, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
Oncology Nurse Navigators Take on COVID-19 Challenge
Web Exclusives published on May 26, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
The Impact of COVID-19 on Cancer Research and Investigational Studies
Web Exclusives published on May 19, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
COVID-19: Impact on Telehealth
Web Exclusives published on May 19, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
Employers and the Impact of COVID-19
Web Exclusives published on May 19, 2020 in AVBCC COVID-19 Webcast Series, COVID-19
Last modified: May 5, 2020